{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:41:23Z","timestamp":1792100483755,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.euros.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T13:09:51Z","timestamp":1649336991000},"page":"72-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Real-world Early Outcomes and Retreatment Rates Following Water Vapour Ablative Therapy for Symptomatic Benign Prostatic Hyperplasia"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2889-5494","authenticated-orcid":false,"given":"Danielle","family":"Whiting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Noureldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehia","family":"Abdelmotagly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brittain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govindaraj","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hindley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2022.03.006_b0005","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1038\/s41598-017-06628-8","article-title":"The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.euros.2022.03.006_b0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/JU.0000000000001778","article-title":"Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rez\u016bm water vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"206","author":"McVary","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2022.03.006_b0015","first-page":"159","article-title":"Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rez\u016bm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"9","author":"Darson","year":"2017","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euros.2022.03.006_b0020","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.juro.2015.10.181","article-title":"Minimally invasive prostate convective water vapour energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"195","author":"McVary","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2022.03.006_b0025","first-page":"207","article-title":"Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia","volume":"8","author":"Dixon","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euros.2022.03.006_b0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41391-017-0022-9","article-title":"Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience","volume":"21","author":"Mollengarden","year":"2018","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euros.2022.03.006_b0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.purol.2020.05.004","article-title":"Treatment of benign prostate hyperplasia using the Rezum\u00ae water vapor therapy system: results at one year","volume":"30","author":"Alegorides","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.euros.2022.03.006_b0040","first-page":"8802","article-title":"Five year results of the prospective randomised controlled prostatic urethral L.I.F.T. study","volume":"24","author":"Roehrborn","year":"2017","journal-title":"Can J Urol"},{"key":"10.1016\/j.euros.2022.03.006_b0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.02.008","article-title":"Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial","volume":"80","author":"Abt","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2022.03.006_b0050","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1007\/s00345-020-03140-z","article-title":"Second generation of temporary implantable nitinol device (iTIND) in men with LUTS: 2 year results of the MT-02-study","volume":"38","author":"Kadner","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2022.03.006_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2017.10.023","article-title":"Three-year outcomes of the prospective, randomized controlled Rez\u016bm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"111","author":"McVary","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.euros.2022.03.006_b0060","series-title":"Male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)","author":"Gravas","year":"2021"},{"key":"10.1016\/j.euros.2022.03.006_b0065","series-title":"Rez\u016bm for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. Medical technologies guidance MTG49","author":"National Institute of Health and Care Excellence","year":"2020"},{"key":"10.1016\/j.euros.2022.03.006_b0070","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1089\/end.2020.0177","article-title":"Comparative postoperative outcomes of Rez\u016bm prostate ablation in patients with large versus small glands","volume":"34","author":"Bole","year":"2020","journal-title":"J Endourol"},{"key":"10.1016\/j.euros.2022.03.006_b0075","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1007\/s00345-020-03548-7","article-title":"Rezum therapy for patients with large prostates (\u226580 g): initial clinical experience and postoperative outcomes","volume":"39","author":"Garden","year":"2021","journal-title":"World J Urol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168322000581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168322000581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:06:56Z","timestamp":1762978016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168322000581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":15,"alternative-id":["S2666168322000581"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2022.03.006","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Early Outcomes and Retreatment Rates Following Water Vapour Ablative Therapy for Symptomatic Benign Prostatic Hyperplasia","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}